Navigation Links
Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer
Date:11/13/2008

LAUSANNE, Switzerland, Nov. 13 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced that the New Drug Application (NDA) for the 6 month formulation of Trelstar(R) (triptorelin pamoate) has been accepted for filing by the United States (U.S.) Food and Drug Administration (FDA). Trelstar(R) is a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic prostate cancer. Once approved, Trelstar(R) will be commercialised in the U.S. by Watson Pharmaceuticals, Inc.

"Last September we announced the filing of the product with the European Agencies, under the name Decapeptyl(R). We are proud to have accomplished the simultaneous filings of Trelstar(R) and Decapeptyl(R) in both the U.S. and Europe, it's a great achievement for us," said Rolland-Yves Mauvernay, president and founder of Debiopharm Group. "This demonstrates our ability to work effectively not only with different regulatory agencies, but also different partners. Furthermore, our FDA inspected research development and production facility, Debio R.P., will produce both products for global distribution."

The NDA for the 6 month formulation of Trelstar(R) is supported by data from a phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer. The results showed that 97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of the patients maintained serum testosterone levels below castrate level (defined as < 1.735 nmol/L or 50 ng/dL) from week 8 to 48. These efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month formulations of Trelstar(R), which are already marketed by Watson Pharmaceuticals, Inc.

About Deb
'/>"/>

SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
2. Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories
3. In a Down Economy, Womens Health Company Announces Growth
4. R&Q Solutions, LLC Announces Launch to Serve Regions Medical Device Industry
5. WellPoint Announces Second Annual Innovation Event
6. CVS Caremark All Kids Can Announces the Opening of a Boundless Playground in Los Angeles to Serve Children of All Abilities
7. Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform
8. HealthCentral Announces New Condition-Specific Ad Service to Offer Marketers the Highest Qualified Audiences
9. Wound Management Technologies, Inc. Announces FDA Clearance of 510k
10. GLEH LA, a Nonprofit Affiliate of Gay & Lesbian Elder Housing, Announces New Program Director
11. Governor Rendell Announces the Passing of Lt. Gov. Catherine Baker Knoll
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... In a piece published July ... of plastic surgery and explained why people should not shy away from their own ... excesses of the few and celebrate it for the modern wonder that it is.” ...
(Date:7/27/2015)... ... ... North Central Surgical Center Hospital will be holding twice-monthly joint wellness classes for ... along with their friends and family members, to attend. The classes take place on ... [Tue due to Labor Day], Oct 5, Nov 2, Dec 7) beginning at 9 ...
(Date:7/27/2015)... ... 27, 2015 , ... A Harris County jury awarded a group of Texas ... promoter Robert Kubbernus based on findings of fraud and violations of the Texas Securities ... court in Cause No. 2010-09675; Jo Ann Schermerhorn, et al v. CenturyLink, Inc. and ...
(Date:7/27/2015)... ... 2015 , ... BESLER Consulting today announced the publication of ... Medicare and Medicaid Services (CMS) provides each hospital affected by the HRRP with ... the QualityNet Hospital-Specific Report (HSR), this report contains a variety of insights that ...
(Date:7/27/2015)... ... 2015 , ... For a limited time, Huntington Beach dentist , Dr. ... a great time to change up a look or to simply brighten a smile. ... your self-esteem. Over time, the enamel coating can become worn and can expose more ...
Breaking Medicine News(10 mins):Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 2Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 3Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 4Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 5Health News:Fryar Law Firm Announces: Jury Awards $19 Million to Investors in Houston Space Teleport 6Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 3
... are known to be good for lowering cholesterol and ... reported benefit: they appear to slow decline in lung ... According to researchers in Boston, it may be statins ... , Their findings were published in the second issue ...
... hire an ad agency; at,least not initially especially if you ... an agency can,t come up with something great. It,s,just that ... Most clients follow tradition process in attempting to find ... develop a,short list of 3 agencies and ask for a ...
... Educate Chicagoans, CHICAGO, Oct. 11 Continuing ... of Chicago, SAVE THE PATIENT, a,not-for-profit patient-focused organization, ... Chicago Access Network. "Community Health Hotline" will,air Monday, ... 21., Monday,s program will feature a frank ...
... /Xinhua-PRNewswire/ -- On,October 10, 2007, Synutra International, Inc. ... dairy-based nutritional products,for infants, children and adults, received ... the Company,s common stock is no longer subject ... October 5, 2007 of the,Company,s quarterly report on ...
... Monday will be a little,cooler for the patients ... the entire Washington Capitals team will make their annual,visit. ... raise money for,cancer research, Courage Caps., Courage Caps ... the season at Capitals home games and online at ...
... who overcome breast cancer have every reason to celebrate. ... a heart damaged by life-saving cancer therapies, a growing ... today including new treatments still under development ... Jones, Ph.D., an exercise physiologist and assistant professor in ...
Cached Medicine News:Health News:Statins reduce loss of function, keeping old lungs young - even in smokers 2Health News:A New Way to Discover Marketing Ideas 2Health News:Patient Empowerment -- Medication Error 2Health News:Nasdaq Informs Synutra that the Company's Filing Delinquency has been Cured 2Health News:Breast cancer awareness calls for cardiovascular awareness 2Health News:Breast cancer awareness calls for cardiovascular awareness 3
(Date:7/27/2015)... and PITTSBURGH , July 27, 2015 ... it will hold its extraordinary general meeting of shareholders in ... PRGO ; TASE) at the Okura Hotel Amsterdam on ... (CET). Among other agenda items at the ... the approval, under article 2:107a of the Dutch Civil Code, ...
(Date:7/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rq47bp/global_pressure ... Pressure Relief Devices Market 2015-2019" report to their ... to grow at a CAGR of 4.41% over the ... Market 2015-2019, has been prepared based on an in-depth ... covers the Americas, and the APAC and EMEA; it ...
(Date:7/27/2015)... PLEASANTON, Calif. , July 27, 2015  QT ... the "Group"), a global company engaged in the design, ... minimally invasive treatment of vascular disease, has entered into ... for up to US$13.14 million convertible bond investment. This ... help boost its growth to the next milestone. ...
Breaking Medicine Technology:Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 2Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 3Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 4Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 5Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 6Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 7Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 8Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 9Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 10Global Pressure Relief Devices Market 2015-2019 with ArjoHuntleigh, Hill-Rom, Paramount Bed Holdings & Stryker Dominating 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3
... , SCOTTSDALE, Ariz. , Jan. 22 Matrixx Initiatives, ... financial results for the fiscal 2010 third quarter, ended December 31, ... January 25, 2010 . An earnings conference call will be held the ... AM ET . , To access the teleconference, please call (888) 452-4006 ...
... ... Called Ampyra, to Improve Walking for People With All Types of ... The U.S. Food and Drug Administration has approved the ... Therapeutics) for its ability to improve walking speed in people with ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2010 Financial Results 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
... For delivery of medication as well as ... refillable, closed dilution, high volume, continuous medication ... therapy to patients. Its 200 ml reservoir ... to 8 hours of nebulized medication delivery ...
Nebulizer Adapter Kit 6"...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
Medicine Products: